Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.

“There are limited therapeutic options to treat this serious medical condition and the clinical community is eagerly awaiting a new safe and effective prokinetic therapy.”

Ulimorelin has previously shown the ability to enhance gastric emptying in patients with severe diabetic gastroparesis. The present analysis focused on the ability of this drug to relieve nausea and vomiting, which are the most serious and potentially life-threatening complications of this disorder. Consistent with its effects on gastric emptying, ulimorelin significantly reduced nausea and vomiting and improved overall symptomatology. These results further support ulimorelin’s future role in the effective management of this debilitating condition.

“We are very pleased that the study results have been selected for presentation at this esteemed forum,” said Gordana Kosutic, M.D., Vice President, Clinical and Regulatory Affairs for Tranzyme. “There are limited therapeutic options to treat this serious medical condition and the clinical community is eagerly awaiting a new safe and effective prokinetic therapy.”

The presentation will be given by Richard McCallum, M.D., Professor and Founding Chairman of the Department of Internal Medicine, Texas Tech University Health Sciences Center at El Paso, and a Clinical Advisory Board member of Tranzyme, at the Neurogastroenterology and Motility Distinguished Abstract Plenary Session on Monday, May 3^rd at 4:15pm EDT in Rooms 283-285 of the Ernest N. Morial Convention Center.